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SUMMARY
Since there are no studies evaluating the participation of the complement system (CS) in Jorge Lobo’s disease and its activity
on the fungus Lacazia loboi, we carried out the present investigation. Fungal cells with a viability index of 48% were obtained
from the footpads of BALB/c mice and incubated with a pool of inactivated serum from patients with the mycosis or with sterile
saline for 30 min at 37 oC. Next, the tubes were incubated for 2 h with a pool of noninactivated AB+ serum, inactivated serum,
serum diluted in EGTA-MgCl
2
, and serum diluted in EDTA. The viability of L. loboi was evaluated and the fungal suspension was
cytocentrifuged. The slides were submitted to immunofluorescence staining using human anti-C3 antibody. The results revealed
that 98% of the fungi activated the CS by the alternative pathway and no significant difference in L. loboi viability was observed
after CS activation. In parallel, frozen histological sections from 11 patients were analyzed regarding the presence of C3 and IgG
by immunofluorescence staining. C3 and IgG deposits were observed in the fungal wall of 100% and 91% of the lesions evaluated,
respectively. The results suggest that the CS and immunoglobulins may contribute to the defense mechanisms of the host against
L. loboi.
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INTRODUCTION
Lacazia loboi is the etiological agent of Jorge Lobo’s disease25, a
chronic cutaneous-subcutaneous mycosis first described by Jorge de
Oliveira Lobo in 1931 in a patient from the Amazon region13. This
mycosis occurs predominantly in Brazil, which accounts for 295 of a
total of 458 cases of the disease17, and affects mainly rural workers
that live in constant contact with vegetation and soil, such as the rubber
tree tappers from the Amazon12,17.
In skin lesions, L. loboi is characterized by a round or oval shape, a
thick well-refringent cell wall, a homogenous or granular cytoplasm,
and a cell size ranging from 6 to 12 µm in diameter. The fungus reproduces
by single or multiple budding, presenting a chain-like arrangement in
which individual cells are interconnected by tube-like structures12.
Electron microscopic analysis shows that L. loboi possesses various
nuclei and that its cytoplasm contains mitochondria, endoplasmic
reticulum, ribosomes, vesicles and lipid droplets9,22,23,29. Its cell wall is
trilaminar and the outermost layer is lined with scales arranged like
tiles on a roof2.
The viability of L. loboi from skin lesion biopsies of patients is
donely using fluorescein diacetate and ethidium bromide dyes and has
shown a rate ranging from 21 to 46%, and that a large number of
fungal cells present in the lesions do not contain any structure,
resembling empty capsules, which correspond to inviable cells26 as
suggested by SESSO & BARUZZI22.
One peculiarity of L. loboi is the fact that the fungus has not been
cultured in artificial media so far despite numerous attempts8,12,18.
However, the development of an experimental model of Jorge Lobo’s
disease in BALB/c mice, which show histological alterations similar
to the human disease with a large number of viable fungi14, has
contributed to the study of this mycosis.
Studies investigating the immunological aspects of Jorge Lobo’s
disease are still scarce. In 2004, VILANI-MORENO et al.28 determined
the cytokine profile in the culture supernatant of peripheral blood
mononuclear cells from 15 patients with the mycosis and observed the
predominance of a Th2 profile. In a previous study, evaluation of serum
immunoglobulins revealed increased levels of IgG, IgA and IgM in
52%, 29% and 5% of patients, respectively20, in agreement with the
finding of a Th2 profile in these patients. Quantification of the serum
C3 fraction of complement showed elevated levels of this protein in
71.4% of patients16.
The activation of the complement system (CS) by the classical,
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alternative or lectin pathway produces chemotactic factors,
anaphylatoxins and opsonins which are important in the defense against
microorganisms. Since no study has been done so far evaluating the
participation of the complement in Jorge Lobo’s disease and its activity
on the fungus Lacazia loboi, we carried out the present investigation.
MATERIAL AND METHODS
Fungal suspension: L. loboi was obtained from the footpads of
BALB/c mice previously inoculated for maintenance of the strain14.
The animals were sacrificed 10 months post-inoculation and the hind
footpads were removed and macerated in sterile saline. The fungal
suspension (pool) obtained was evaluated regarding the number of fungi
and viability index and subsequently used for evaluation of complement
activity.
Determination of fungal viability: Fungal viability was
determined by vital staining with fluorescein diacetate-ethidium
bromide (FD-EB)6 as described for L. loboi by VILANI-MORENO &
OPROMOLLA26. Fungi showing a green fluorescent color were
classified as viable and those becoming orange were classified as
inviable. Percent viability was determined by counting 100 fungal cells.
Fungal concentration in the suspension: The concentration of
fungi was determined by cell counting in a Neubauer chamber and the
results are expressed as absolute number.
Blood serum: A pool of sera from patients with Jorge Lobo’s
disease and a pool of sera from healthy AB individuals (normal human
serum - NHS), as human complement source, were used. The sera
were divided into aliquots and stored at -20 ºC.
Test for the evaluation of complement activity on L. loboi: The
technique of KRETTLI et al.11 was used. Briefly, 11 tubes containing
0.2 mL of the fungal suspension (2 x 106 cells) were incubated at 37 ºC
for 30 min with 0.2 mL inactivated patient serum (tubes 1 to 5) or
sterile saline (tubes 6 to 11). Next, the tubes were centrifuged at 1500
rpm for five min and washed once with sterile saline. Fungi in tubes 1
and 6 were resuspended in 0.5 mL noninactivated NHS, tubes 2 and 7
in inactivated NHS, tubes 3 and 8 in noninactivated NHS diluted 1:2 in
10 mM EGTA [ethylene glycol-bis(β-aminoethyl ether)-N,N,N‘,N‘-
tetraacetic acid] containing 2 mM MgCl
2 
(Sigma-Aldrich Co., St. Louis,
MO, USA), tubes 4 and 9 in 0.5 mL noninactivated NHS diluted 1:2 in
EDTA [ethylenediaminetetraacetic acid] (Sigma-Aldrich), tubes 5 and
10 in noninactivated NHS diluted 1:2 in sterile saline, and tube 11 was
resuspended in sterile saline only (control tube of the fungal
suspension). The EGTA-MgCl
2
 and EDTA solutions were used to block
the classical pathway of CS activation7 and the classical and alternative
activation pathways24, respectively. The tubes were incubated at 37 ºC
for two h. Next, the tubes were centrifuged at 1500 rpm for five min
and the fungal suspension was resuspended in 0.5 mL sterile saline.
The viability of the fungi was evaluated using the FD-EB technique as
described above. The remaining fungal suspension was analyzed by
immunofluorescence using anti-C3 monoclonal antibody.
Fungal immunofluorescence: Fungal cells were cytocentrifuged
at 1500 rpm for five min and slides were air dried and fixed in acetone
for five min. After washing in phosphate-buffer saline (PBS), pH 7.2,
and drying, the slides were placed in a humid chamber and conjugate
(fluorescein isothiocyanate-conjugated human anti-C3c monoclonal
antibody; Dako Co., Carpinteria, CA, USA) diluted 1:200 in Evans
blue-Tween 20 was added to each orifice. The slides were incubated
for 30 min at 37 ºC, washed, dried and mounted in buffered glycerine.
Next, 100 fluorescent and non-fluorescent fungal cells were counted
under a fluorescence microscope.
Collection of skin lesions: A fragment of the skin lesions from 11
patients with Jorge Lobo’s disease from the State of Acre was collected
by biopsy or by complete surgical removal of the lesion, as indicated for
each case. The fragment was immersed in OCT (Tissue-Tek, Sakura
Finetechnical Co., Tokyo, Japan), frozen in liquid nitrogen and stored in
a freezer at -80 ºC until the time of use. The frozen material was cut with
a cryostat at -26 ºC into 4-µm thick sections, and the sections were
mounted on silanized slides (Sigma-Aldrich) for subsequent detection
of immunoglobulins and complement by immunofluorescence.
Immunofluorescence study of skin lesions: The slides containing
the sections obtained from frozen tissue were kept overnight at 4 ºC and
were then fixed in ice-cold acetone for 10 min. Next, the slides were
washed three times in PBS, air dried, and placed in a humid chamber.
The sections were incubated at 37 ºC for 30 min with the following
fluorescein conjugates: total anti-Ig, anti-IgG, anti-IgA, anti-IgM, and
anti-C3c (Dako) at dilutions of 1:800, 1:800, 1:200, 1:200, and 1:200,
respectively. The slides were then washed, dried and mounted in buffered
glycerin containing Evans blue. Sections in which the conjugate was
omitted were used as negative control. The slides were examined under
a fluorescence microscope and evaluated regarding the presence of
immunoglobulins and complement deposited in the fungal wall inside
granulomas. The slides were evaluated by three observers and the results
are expressed on a semiquantitative scale, where 0 = absent, 1+ = minimal,
2+ = discrete, 3+ = moderate, and 4+ = intense.
RESULTS
The results regarding the determination of viability of L. loboi and
C3 fixation with the different treatments are shown in Table 1. The
initial viability of the fungus was 48% and this index did not change
significantly after complement activation for two h. Complement
fixation was 84% and 85% with NHS in the presence and absence of
patient serum, respectively. When NHS was diluted 1:2 in sterile saline,
these percentages fell to 75% and 78%. Dilution of NHS in EGTA-
MgCl
2
 led to complement activation by the alternative pathway, with
98% fixation (Fig. 1). No C3 fixation was observed when NHS was
diluted in EDTA and no fluorescence was observed for tube 11 since
the fungi were only incubated with sterile saline. It should be noted
that the assay for the evaluation of complement activity on L. loboi
was carried out using three different fungal suspensions and similar
results were obtained for the three assessments.
The presence or absence of immunoglobulins and complement in
the granulomas of skin lesions from patients with Jorge Lobo’s disease
is shown in Table 2. Deposits involving fungi included IgG, IgA, IgM
and C3 in 91%, 27%, 18% and 100% of the patients, respectively. In
most cases these deposits were characterized by a homogenous linear
staining of the fungal cell wall (Fig. 2). No staining was observed in
the sections used as control in which the conjugate was omitted.
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DISCUSSION
The CS is one of the main effector mechanisms of humoral as well
as innate immunity. This system can be activated by the classical,
alternative or lectin pathway. CS activation by the classical pathway is
commonly initiated by the formation of soluble antigen-antibody
complexes or by the binding of an antibody to an antigen on the
appropriate target such as, for example, a fungal cell. The alternative
pathway, on the other hand, does not depend on the participation of
antibodies, therefore being a component of the innate immune system.
This activation pathway involves four serum proteins (C3, factor B,
factor D and properdin) and is initiated by different components on
the cell surface that are foreign to the host. Both bacteria and fungi
possess constituents in their cell wall that can activate the alternative
pathway1,10. Similar to the alternative pathway, the lectin pathway does
not depend on antibodies for its activation. Lectins are proteins that
bind to carbohydrates (mannose) present on the surface of
microorganisms. Binding of mannose-binding lectin (MBL) to mannose
residues of the microorganism, together with serine protease, initiates
the complement cascade through the C4 component1,10.
In the present study, L. loboi was found to be able to activate the
Table 2
Presence of immunoglobulins and complement in granulomas of skin lesions
from patients with Jorge Lobo’s disease
Patient Total Ig IgG IgA IgM C3
11 2+ 2+ 0 0 2+
12 1+ 1+ 1+ 0 4+
13 0 0 0 0 4+
14 3+ 2+ 0 1+ 1+
15 3+ 3+ 2+ 1+ 3+
16 1+ 1+ 0 0 1+
17 2+ 2+ 0 0 3+
18 1+ 1+ 0 0 1+
19 1+ 1+ 0 0 1+
10 3+ 3+ 1+ 0 2+
11 3+ 3+ 0 0 2+
Median 2+ 2+ 0 0 2+
0 = absent; 1+ = minimal; 2+ = discrete; 3+ = moderate; 4+ = intense.
Table 1
Evaluation of complement activity on the fungus Lacazia loboi
L. loboi Patient NHSa Chelating Viability C3 fixation
serum agent (%) (%)
+ + NIb - 45 84
+ + Ic - 44 -
+ + NI (1:2) EGTA-MgCl
2
46 96
+ + NI (1:2) EDTA 45 -
+ + NI (1:2) - 44 75
+ - NI - 44 85
+ - I - 45 -
+ - NI (1:2) EGTA-MgCl
2
44 98
+ - NI (1:2) EDTA 46 -
+ - NI (1:2) - 44 78
+ - - - 47 -
a. normal human serum, b. noninactivated, c. inactivated.
Fig. 1 - C3 deposit in the cell wall of Lacazia loboi. Fungal suspension treated with normal
human serum. Immunofluorescence (magnification: 400x).
Fig. 2 - C3 deposit in the cell wall of Lacazia loboi in a skin lesion from a patient with Jorge
Lobo’s disease. Immunofluorescence (magnification: top, 200x and bottom, 400x).
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CS in vitro by the alternative pathway. Several studies have evaluated
the activation of the CS by fungal cells. RAY & WUEPPER19 reported
that Candida albicans activates the CS in vitro by the alternative
pathway, producing chemotactic factors, anaphylatoxins and opsonins
that might be important in the defense against this agent. Similarly,
SWAN et al.24 described alternative activation of the CS by the fungus
Trichophyton rubrum and suggested that the complement plays a role
in the defense against these microorganisms. In paracoccidioido-
mycosis, CALICH et al.5 demonstrated that P. brasiliensis activates
the CS by the alternative pathway, resulting in opsonization of the
fungus and facilitation of macrophage-mediated phagocytosis. In
another study, the authors4 evaluated lysis of P. brasiliensis by the CS
and reported a mortality rate of 30 to 50%. More recently, MUNK &
SILVA15 showed that the fungus P. brasiliensis activates the CS by the
alternative pathway but this event does not reduce its viability.
In the present study, CS activation did not reduce the viability of
L. loboi, probably because of the short period of incubation (2 h).
Incubation of the fungus in noninactivated NHS (tube 6) and only in
sterile saline (tube 11, control) for 24 h at 37 ºC did not yield satisfactory
results, with the loss of fungal viability. In a previous study, we have
demonstrated that a temperature of 37 ºC is inefficient in maintenance
of L. loboi viability, since viable fungi were no longer observed by the
third day of incubation26. In addition, since L. loboi has not been cultured
in artificial media its viability cannot be determined by colony count
technique, a method commonly employed for fungi21.
As observed in this study, the presence of immunoglobulins and
C3 in Jorge Lobo’s granulomas suggests that antibodies bound to the
fungi may function as opsonin and facilitate macrophage-mediated
phagocytosis of the microorganism, in addition to CS activation. This
activation by the classical pathway would potentiate opsonization,
favoring endocytosis and destruction of the microorganism by
microbicidal mechanisms of the phagocytic cells. This hypothesis is
supported by the finding of fungi with morphological features of
inviability in the inflammatory infiltrate27. Furthermore, the observation
in the present study of predominantly IgG deposits might be due to the
fact that Jorge Lobo’s disease is a chronic infectious disease and,
consequently, the antigen stimulus is constant.
C3 was detected in all lesions analyzed, a finding that may also be
the result of the fungus ability to activate the CS by the alternative
pathway. However, since we observed IgG deposits in the fungal wall,
it is possible that C3 results from classical pathway activation through
an antigen-antibody reaction. The finding of plasma cells in the
inflammatory infiltrate which, although not abundant, were always
detected in the lesions analyzed, agrees with this view27.
The present results agree with those obtained for peripheral blood
of patients with Jorge Lobo’s disease. In this respect, studies have
demonstrated the participation of the humoral immune response in
Jorge Lobo’s disease, with patients showing high serum levels of
immunoglobulins and of the C3 component of the complement16,20. In
addition, the present findings support those reported by our group in a
previous study demonstrating that patients with the mycosis present
an altered cytokine pattern represented by the predominance of a Th2
profile28.
The detection of antibodies and complement in tissue lesions was
previously described in paracoccidioidomycosis by BIAGIONI et al.3.
They demonstrated the presence of IgG and C3 in the fungal wall in
the center of the paracoccidioidal granuloma and suggested that specific
antibodies bound to the fungus blocking antigen diffusion from the
granulomas and activate the CS, thus facilitating the destruction of
parasites by phagocytosis or lysis.
Taken together, the present results show that the fungus L. loboi is
able to activate the CS by the alternative pathway. The presence of C3
and immunoglobulins in skin lesions from patients with Jorge Lobo’s
disease suggests the participation of these proteins in the defense
mechanisms of the host against the fungus.
RESUMO
Ativação in vitro e in situ do sistema complemento pelo fungo
Lacazia loboi
Considerando que não existe nenhum estudo avaliando a
participação do sistema complemento (SC) na doença de Jorge Lobo e
sua atividade sobre o fungo Lacazia loboi, realizamos o presente
trabalho. Os fungos foram obtidos dos coxins plantares de camundongos
BALB/c com índice de viabilidade de 48% e, em seguida, foram
incubados com pool de soro inativado de pacientes ou com solução
salina estéril (SSE) por 30 min, a 37 ºC. Os tubos foram incubados,
por 2 h, com pool de soro AB+ sem inativar, inativado, diluído em
EGTA-MgCl
2 
e EDTA. A viabilidade do L. loboi foi avaliada e a
suspensão fúngica foi citocentrifugada. As lâminas foram submetidas
à técnica de imunofluorescência empregando o anticorpo anti-C3
humano. Os resultados revelaram que 98% dos fungos ativaram o SC
pela via alternativa e que não houve diferença significante na viabilidade
do L. loboi após ativação do SC. Em paralelo, cortes histológicos
congelados de 11 pacientes foram avaliados quanto à presença de C3 e
IgG, pela técnica de imunofluorescência. Foram encontrados depósitos
de C3 e de IgG na parede dos fungos em 100% e 91% das lesões
avaliadas, respectivamente. Os resultados sugerem que o SC e as
imunoglobulinas poderiam contribuir nos mecanismos de defesa do
hospedeiro contra o L. loboi.
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